BOSUTINIB MONOHYDRATE (bosutinib monohydrate) by PharmaIN is tki. Approved for • adult, older with chronic phase ph+ chronic myelogenous leukemia (cml), newly-diagnosed and 3 more indications. First approved in 2025.
Drug data last refreshed 20h ago
TKI. Bosutinib inhibits the BCR-ABL kinase that promotes CML; it is also an inhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms of BCR-ABL kinase expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L…
Worked on BOSUTINIB MONOHYDRATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.